US Stem Cell Inc (USRM)

[Havoc23]

Many years, because the FDA hasn't been friendly towards emerging biotechs, especially in the stem cell sector. In fact the FDA has made it nearly impossible for these emerging stem cell companies to progress.

That is the whole point of the Cures Act and the RMAT designations. To spur innovation in these new fields, allowing the companies to progress through the EXPENSIVE and burdensome FDA process, only available to big pharma in the past.

And guess what?! The FDA has a new chief in town, Scott Gottlieb, who just so happens to be a HUGE proponent of adult stem cell therapies. ADULT stem cells, the kind usrm is applying for RMAT designation.

Out with the old, in with the new. Usrm is getting ready to take over and it looks like they have a few new friends to help make it happen. One of their new friends apparently likes to throw money their way. Hmmm wonder why. Wonder what they know.